FRCA Notes


Methohexital


  • Induction of anaesthesia (1 - 2mg/kg) for short procedures due to short duration of action e.g.:
    • ECT
    • Short surgeries
    • Pre-hospital induction

  • Methohexital is formulated as a white powder containing:
    • The sodium salt of methohexital
    • 6% Na2CO3 by weight
  • The addition of water creates an alkaline (pH 11) racemic mixture of 1% methohexital solution, of pKa 7.9
  • The shelf-life is 6 weeks at room temperature (less if dextrose or saline is used)
  • The solution is bacteriostatic

Absorption

  • With a pKa of 7.9, it is 76% unionised at pH 7.4 (vs. 60% thiopental)
  • Methohexital has a faster onset than thiopental due to:
    • Greater unionised fraction at physiological pH
    • Reduced protein binding therefore more free drug

Distribution

  • It is only 60% protein bound (vs. 80% thiopental)
  • It has a volume of distribution of 2L/kg

Metabolism

  • High hepatic clearance
  • Metabolised to hydroxymethohexitone, which has minimal hypnotic activity

Excretion

  • Clearance 11ml/kg/min
  • Half life of 3-5hrs

Respiratory

  • Less respiratory depression than other agents but greater degree of laryngospasm

Cardiovascular

  • Treater compensatory tachycardia than thiopental so MAP falls less

Neurological

  • Excitatory phase prior to loss of consciousness
  • Can precipitate seizures in those with epilepsy

Renal

  • Similar renal effects to thiopentone

Other

  • Can cause pain on injection and similar effects to thiopental following intra-arterial injection
  • Doesn't cause histamine release